Glandokort

Glandokort is a peptide complex bioregulator, classified as a Cytomax for the adrenal cortex in the Khavinson system. It is manufactured by extraction from adrenal tissue of young calves under 12 months old using a patented process developed at the St. Petersburg Institute of Bioregulation and Gerontology. The active fraction is identified as peptide complex A-13 and contains short peptides with molecular weights up to approximately 10 kDa.

The Khavinson bioregulator program produced two parallel compound classes. Cytomaxes are organ-specific peptide extracts containing heterogeneous mixtures of peptides. Cytogens are short synthetic peptides designed to reproduce a single active fragment from a Cytomax. For the adrenal cortex, the Cytomax is Glandokort. A corresponding defined-sequence adrenal Cytogen is not part of the widely marketed Khavinson product line.

The compound is described in Khavinson group publications on peptide bioregulation, including the 2014 review and the 2020 short-peptide DNA-interaction paper. Independent confirmation by Western groups is sparse.

The Human Evidence

The compound-specific clinical evidence base consists of:

• Russian-institution clinical observation studies in elderly patients with subjective fatigue and stress-related symptoms
• Manufacturer documentation describing improvement in standard markers of well-being after 30-day courses
• Use as part of broader Khavinson geroprotective protocols in Russian medical centers
• Limited data on hormonal parameters; full hormonal-axis monitoring with rigorous endpoints has not been published

Independent Western replication is absent. PubMed indexing for Glandokort returns no English-language clinical trials as of May 2026. No registered ClinicalTrials.gov study exists.

The compound's claims sit in a particularly evidence-thin area. "Adrenal fatigue" is not a recognized medical diagnosis. Diagnosed adrenal insufficiency (Addison's disease, secondary adrenal insufficiency) requires biochemical confirmation with cortisol and ACTH testing and is treated with hydrocortisone replacement under physician supervision. The wellness-market claims for Glandokort target a symptom cluster (fatigue, stress sensitivity, low energy) that overlaps with many other conditions and is not biochemically characterized in standard ways. Honest evaluation requires acknowledging both the compound's positioning and the conceptual problems with the underlying clinical category.

Regulatory and Legal Status

FDA. No approval. Not listed on bulk drug substances list. Importation permitted only as a research chemical labeled "not for human consumption."

EMA. No approval.

Russia. Registered as a biologically active dietary supplement. Sold in oral capsule and sublingual liquid formats through the Khavinson distribution network.

WADA. Not on the 2026 Prohibited List. Compounds claimed to affect the HPA axis merit caution in the doping context, since exogenous corticosteroids and ACTH are prohibited.

The proposed mechanism follows the Khavinson short-peptide bioregulation model with adrenal-cortex tissue specificity.

Cellular entry and DNA interaction. Short peptides from the Glandokort complex are hypothesized to enter adrenal cortical cells through peptide transporters, reach the nucleus, and bind DNA in promoter regions of adrenal-specific genes. The Khavinson model treats this as the basis for tissue-selective gene-expression modulation.

Proposed downstream effects. Khavinson group publications describe Glandokort effects on:

• Adrenal cortical cell protein synthesis
• Modulation of expression of genes related to steroidogenesis
• Improvement in adrenal cortical morphology in animal aging models
• Effects on adrenal-stress response markers

Specific gene-expression changes have not been mapped in independent transcriptomic studies. The tissue-specificity claim rests on functional observations in animal tissue cultures and on the broader Khavinson framework rather than on direct molecular characterization for Glandokort specifically.

Pharmacokinetics. Bovine-origin peptide complexes face the same challenge as any orally administered peptide: gut hydrolysis to free amino acids and short fragments. The Khavinson group has proposed that pharmacological signaling occurs at the gut-mucosa interface and is propagated systemically through neural and humoral pathways rather than requiring intact peptide delivery to the adrenal cortex. Direct measurement of plasma peptide levels after Glandokort administration has not been published.

Human pharmacokinetic data is not published in any English-language peer-reviewed journal.

Russian-institution observational data describes the following effects:

• Subjective improvement in fatigue and stress tolerance
• Improvement in markers of general well-being in elderly populations
• Modest effects on sleep quality and morning energy
• Use as an adjunct in post-illness recovery protocols
• Effects on cortisol-related markers (limited data)

Research-chemical user reports outside Russia are infrequent compared with the Cytogen-class peptides. The Cytomax oral format dominates retail distribution.

None of these effects has been quantified in a placebo-controlled trial. The observational data is non-blinded and produced within the Khavinson network. Effects on diagnosed adrenal disease have not been documented.

No standardized human dosing protocol supported by independent pharmacokinetic data exists for Glandokort.

The Russian retail product is dosed as 1 to 2 capsules once or twice daily during meals for a 30-day course, repeated 2 to 3 times per year. Each capsule contains approximately 10 mg of active adrenal peptide complex.

Sublingual liquid formulations provide 10 mg of active peptide per 1 mL dose, with the rationale that sublingual delivery bypasses first-pass gut hydrolysis.

The course-and-cycle pattern is standard Khavinson protocol. The theoretical rationale is that bioregulator effects persist between cycles through induced gene-expression changes, so continuous dosing is not required. Independent confirmation of cycle-spacing optimization for Glandokort specifically is absent.

Subcutaneous research-chemical use is uncommon for Cytomaxes. Injection of bovine-derived heterogeneous peptide mixtures carries higher infectious and immunogenicity risk than injection of single defined synthetic peptides.

The Khavinson bioregulator class has a benign published adverse-event profile. The Russian manufacturer documentation for Glandokort lists individual intolerance, pregnancy, lactation, and age below 14 years as contraindications. No serious adverse events have been formally reported in Russian-language clinical publications.

The animal-tissue origin creates a distinct safety profile compared with synthetic Cytogens. Theoretical concerns specific to Glandokort include:

• Contamination risk from bovine source tissue
• Theoretical prion-related concerns from bovine-derived products
• Potential immunogenicity from foreign-protein exposure
• Endotoxin risk in any injectable forms

The Russian manufacturer documentation describes sourcing standards and quality controls. Third-party verification of these standards at Western regulatory levels has not been performed.

Long-term human safety data with controlled endpoints does not exist.

For users with diagnosed adrenal disease, the relevant safety consideration is not the compound's direct toxicity profile but the risk of substituting an unproven supplement for evidence-based treatment. Untreated or undertreated adrenal insufficiency is a medically serious condition that can produce adrenal crisis, electrolyte disturbances, and death.

Within the Khavinson system, Glandokort is the adrenal Cytomax. A defined synthetic Cytogen counterpart for the adrenal cortex is not part of the widely marketed product line, so the standard Cytogen-then-Cytomax sequence used for other organ systems does not have a direct analog for adrenal support.

For broader endocrine stacks, Glandokort is combined with Suprefort (pancreatic Cytomax for endocrine pancreas) and Pancragen (pancreatic Cytogen). For HPA-axis comprehensive coverage, Glandokort joins Cerluten (brain Cytomax, hypothalamus-adjacent), and Thymalin (thymus Cytomax, immune coverage that interacts with stress physiology).

No combined-stack human trial has been published. The geroprotective stack rationale is built on the broader Khavinson framework rather than on compound-specific clinical evidence.

External comparators in the conventional medical landscape are diagnosis-specific. True primary adrenal insufficiency requires hydrocortisone replacement, sometimes with mineralocorticoid replacement (fludrocortisone). Secondary adrenal insufficiency requires hydrocortisone replacement and management of the underlying pituitary or hypothalamic cause. None of these conditions has a peptide-supplement substitute. For functional symptoms (fatigue, low energy, stress sensitivity) without diagnosed endocrine disease, the conventional approach is medical workup to rule out organic causes, plus sleep, exercise, nutrition, and stress-management interventions with substantial evidence bases. Glandokort sits outside both clinical pathways.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.